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Pancreaticoduodenectomy (PD) has become in-
creasingly accepted as a safe and appropriate sur-
gical technique for patients with either malignant
or benign diseases of the pancreas and peri-
ampullary region. Nonetheless, the incidence 
of postoperative morbidity remains high and is
currently estimated at 46–59%.1–12 In most re-
ports, the leading cause of morbidity after PD is
attributable to pancreatic leakage,1,2,8,13–15 due
to failure of the pancreatic–enteric anastomosis
to heal. The incidence of pancreatic anastomosis
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Background/Purpose: Pancreatic leakage is a leading cause of morbidity and mortality after pancreatico-
duodenectomy (PD). Pancreaticogastrostomy (PG) has been reported to be associated with a lower pan-
creatic leakage rate and morbidity rate than pancreaticojejunostomy (PJ). This study compared the
preoperative characteristics, surgical risk factors, intraoperative parameters, and postoperative outcome
between PJ and PG.
Methods: From March 1992 to March 2005, a comparative study between PJ and PG for patients with 
periampullary lesions undergoing PD was conducted. A total of 377 consecutive patients underwent PD.
Among them, 188 patients underwent PJ and 189 underwent PG.
Results: The overall mortality, morbidity and pancreatic leakage following PD were 5%, 45.1% and
10.6%, respectively. The mortality, morbidity and pancreatic leakage were 8.9%, 56.4% and 17.6% in the
PJ group, and 2.1%, 33.9% and 3.7% in the PG group (p < 0.001). Mean operative time was 9.3 hours ver-
sus 6.7 hours (p < 0.001), mean blood loss was 1032 mL versus 891 mL (p = 0.064) and mean hospital stay
was 34.8 days versus 26.1 days (p < 0.001) in the PJ and PG groups, respectively. PJ, soft pancreas, pancre-
atic duct stenting, low surgical volume (< 20) and age (> 65 years) were identified as risk factors for pan-
creatic leakage, while PJ, soft pancreas, pancreatic duct stenting and low surgical volume (< 20) were four
significant risk factors for surgical morbidity. Further, PJ, pancreatic leakage, low surgical volume (< 20)
and age (> 65 years) were identified to be surgical risk factors for mortality.
Conclusion: PG is a safer method than PJ following PD as a significantly lower rate of pancreatic leakage,
surgical morbidity and mortality, shorter operation time, and shorter postoperative hospital stay are reported.
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ORIGINAL ARTICLE
of 13.6%,16–19 resulting in mortality rates of 
approximately 8–40% (mean, 12.5%).16–19
Attempts to minimize anastomotic leakage
and minimize complications following PD have
included both pharmacologic prophylactic ap-
proaches as well as various surgical techniques.
For example, simple closure of the pancreatic
duct, use of rubber or fibrin glue to occlude the
main duct, pancreaticoenterostomy with the je-
junum or stomach, PD with or without external
pancreatic duct drainage, pancreatic duct stent-
ing, invaginating end-to-end or end-to-side anas-
tomoses, using an isolated Roux-en-Y limb, one-
versus two-layer suture or duct-to-mucosa anas-
tomosis, and even total pancreatectomy have
been attempted.20–31 Despite the introduction of
these techniques, universal agreement has yet to
be reached regarding the selection or endorse-
ment of any particular variation of pancreaticoje-
junostomy (PJ) as a safer surgical technique that
is less prone to fistula formation.
The recently repopularized option for enteric
drainage of the pancreatic remnant is pancre-
aticogastrostomy (PG), a technique first reported
in dogs in 1934,31 and initially described clinically
by Waugh and Clagett in 1946.32 Although a few
randomized controlled trials revealed no differ-
ence in the incidence of pancreatic leakage be-
tween PJ and PG,33–35 most retrospective reports
suggest that PG is associated with lower pancreatic
leakage and surgical morbidity compared to PJ.
Since the reconstruction method of choice re-
mains controversial, this study was designed to
retrospectively compare patients receiving PJ or
PG following PD to determine whether or not
PG is a safer alternative for pancreatic reconstruc-
tion than PJ.
Methods
Patients and outcome measures
Medical data from 377 patients in Taipei Veterans
General Hospital who underwent PJ or PG fol-
lowing PD between March 1992 and March 2005
inclusive were analyzed. Surgical technique (PJ
versus PG) was selected according to the sur-
geon’s preference.
Surgical risks in terms of surgical mortality,
morbidity, and pancreatic leakage were assessed
and compared by a variety of factors including
surgical technique, patient age, stenting status for
pancreatic anastomosis, consistency of pancre-
atic parenchyma and the surgeon volume in per-
forming PD.
Surgeon volume was according to the total
volume of each surgeon and stratified into three
groups: low (< 10), medium (10–20), and high
(> 20). Surgical mortality was defined as any death
occurring during hospitalization or within 30 days
postoperatively. Delayed gastric emptying was de-
fined as the inability to resume oral intake after
postoperative day 14. To provide direct evidence
of pancreatic anastomosis leakage, upper gastroin-
testinal studies (oral intake of 2 mL methylene
blue dye plus 200 mL water) or fistulogram were
performed in any patient in whom pancreatic
leakage was suspected. Thus, pancreatic leakage
was defined as leak of methylene blue dye into a
drain or positive fistulogram findings at any time
during the postoperative period.
Surgical technique
PD was performed with either the pylorus-
preserving modification or classic resection in-
cluding antrectomy. For reconstruction of PG, 
a 3–4 cm stump of the pancreatic remnant was
freed from the splenic vein and retroperitoneum.
The pancreatic stump was anastomosed and in-
vaginated into the mid-body posterior wall of
the stomach with interrupted two-layer sutures
employing 3-0 silk for the outer layer placed be-
tween the pancreatic capsule and seromuscular
layer of the posterior gastric wall, and 3-0
polyglactin (Vicryl; Ethicon, Somerville, NJ, USA)
for the inner layer placed between the cut edge of
the pancreas and the full thickness of the poste-
rior gastric wall. No duct-to-mucosa anastomosis
was used for PG.
For reconstruction of PJ, end-to-side or end-
to-end anastomosis, duct-to-mucosa, two-layer
sutures were performed with the same suture
W.L. Fang, et al
718 J Formos Med Assoc | 2007 • Vol 106 • No 9
materials as described for PG. Two latex closed-
suction tubes were used to drain the areas near
the pancreatic anastomosis. In patients with pan-
creatic duct stents, a 5F or 8F pediatric feeding
tube was used. After pancreatic reconstruction,
an end-to-side hepaticojejunostomy and an end-
to-side antecolic duodenojejunostomy or gastro-
jejunostomy completed the reconstruction. No
vagotomy was performed in any procedure. A na-
sogastric tube was routinely used to decompress
the stomach posteriorly, which was subsequently
removed when gastric output from the nasogas-
tric tube was less than 500 mL.
Statistical analysis
Statistical analysis was performed using SPSS 
version 13.0 (SPSS Inc., Chicago, IL, USA). Data
are presented as mean ± standard deviation (SD).
Categorical data were compared using χ2 test. The
independent samples t test was employed to com-
pare the means of two groups. Logistic regression
multivariate analysis was carried out to deter-
mine the independent risk factors after PD. A p
value<0.05 was considered statistically significant.
Results
A total of 377 patients underwent PG or PJ fol-
lowing PD. As illustrated in Table 1, 189 patients
received PG and 188 PJ. In the PG group, 132 pa-
tients were male and 57 were female with a mean
age of 66 years. In the PJ group, 129 patients were
male and 59 were female with a mean age of 65.1
years. There was no difference in age and sex dis-
tribution between the two groups. In the PJ group,
a significant higher incidence of ampulla Vater
adenocarcinoma and distal common bile duct
adenocarcinoma were observed, while duodenal
adenocarcinoma and other malignant lesions were
more common in the PG group. Patients receiving
PJ presented with significantly more symptoms
of fever and chills, while jaundice was more
common in PG.
Surgical mortality was lower in the PG group
than in the PJ group (p = 0.000) (Table 2). Surgical
morbidity was also significantly lower in the PG
group regarding overall complications (p = 0.000),
pancreatic leakage (p = 0.000), intra-abdominal
abscess (p = 0.000), and sepsis (p = 0.004). The
mean length of hospital stay was statistically dif-
ferent between the two groups, with 26.1 days in
the PG group and 34.8 days in the PJ group (p =
0.000). Operative time was significantly less in
the PG group (PG, 6.7 ± 1.2 hours; PJ, 9.3 ± 2.0
hours). The PG group had a significantly higher
proportion of patients with small PD diameter
(p = 0.002), and no stenting of the pancreatic
duct (p = 0.000). There was no significant differ-
ence in pancreatic texture between the two groups
(p = 0.098).
Table 3 demonstrates a statistically significant
relationship between pancreatic leakage and each
of: type of anastomosis (p = 0.000); pancreatic
texture (p = 0.032); pancreatic duct stenting (p =
0.000); surgeon volume (p = 0.000); and age (p =
0.031). Multivariate analysis (Table 4) revealed
that the independent risk factors for pancreatic
leakage included type of anastomosis (p = 0.020;
odds ratio [OR], 4.35) and age (p = 0.031; OR,
2.54).
Surgical morbidity was significantly associated
with type of anastomosis (p = 0.000), pancreatic
texture (p = 0.001), pancreatic duct stenting (p =
0.002), and surgeon volume (p = 0.034) (Table 5).
The independent risk factors for surgical morbid-
ity by multivariate analysis included type of anas-
tomosis (p = 0.001; OR, 3.18) and pancreatic
texture (p = 0.003; OR, 2.01) (Table 6). As shown
in Table 7, surgical mortality was significantly as-
sociated with the type of anastomosis (p = 0.009),
pancreatic leakage (p = 0.000), surgeon volume
(p = 0.000), and age (p = 0.039).
Most (87.0%) of the patients were operated
on by experienced surgeons (surgeon volume
> 20). These surgeons had significantly lower sur-
gical mortality rates (2.7%) compared with the
medium-count surgeons (19%) and low-count
surgeons (21.4%) (p = 0.000). Independent risk
factors of surgical mortality included pancreatic
leakage (p = 0.010; OR, 4.21) and surgeon vol-
ume (p = 0.001), with OR of 4.59 for medium
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surgeon volume and 7.27 for low surgeon vol-
ume (Table 8).
Discussion
Since pancreatic leakage is a leading cause of
morbidity and mortality after PD, this study was
performed in order to compare preoperative char-
acteristics, surgical risk factors, intraoperative pa-
rameters, and postoperative outcomes between
PJ and PG in patients who had previously under-
gone PD. The data presented herein identified a
significantly lower rate of pancreatic leakage in
patients who had PG following PD compared to
patients who had PJ after PD (3.7% vs. 17.6%).
These results are different from those cited in
the literature. While only a few controlled ran-
domized studies dealing with the comparison of
PG and PJ following PD have been published,33–35
no significant difference in pancreatic leakage
between PJ and PG was reported. Specifically,
W.L. Fang, et al
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Table 1. Demographic characteristics and clinical presentation of patients undergoing
pancreaticoduodenectomy*
Overall (n = 377) PJ (n = 188) PG (n = 189) p
Periampullary lesions
Ampulla Vater adenocarcinoma 133 (35.3) 80 (42.6) 53 (28.0) 0.003
Pancreatic head adenocarcinoma 18 (13.1) 11 (5.9) 7 (3.7) 0.328
Distal CBD adenocarcinoma 34 (9.0) 27 (14.4) 7 (3.7) 0.000
Duodenal adenocarcinoma 114 (30.2) 40 (21.3) 74 (39.2) 0.000
Chronic pancreatitis 46 (12.2) 25 (13.3) 21 (11.1) 0.517
Other malignancy 20 (5.3) 2 (1.1) 18 (9.5) 0.000
Other benign lesion 12 (3.2) 3 (1.6) 9 (4.8) 0.080
Age (yr) 0.456
Median (range) 68 (15–89) 68 (15–89) 69 (16–85)
Mean ± SD 65.6 65.1 ± 11.6 66.0 ± 12.1
Sex 0.824
Male 261 (69.2) 129 (68.6) 132 (69.8)
Female 116 (30.8) 59 (31.4) 57 (30.2)
Clinical presentation
Jaundice 267 (70.8) 122 (64.9) 145 (76.7) 0.012
Epigastralgia 153 (40.6) 83 (44.1) 70 (37.0) 0.160
Body weight loss 126 (33.4) 71 (37.8) 55 (29.1) 0.075
Diabetes mellitus 63 (16.7) 29 (15.4) 34 (18.0) 0.505
Anorexia/nausea/vomiting 48 (12.7) 22 (11.7) 26 (13.8) 0.550
Upper gastrointestinal bleeding 24 (6.4) 16 (8.5) 8 (4.2) 0.089
Diarrhea/steatorrhea 23 (6.1) 13 (6.9) 10 (5.3) 0.510
Others 141 (37.4) 78 (41.5) 63 (33.3) 0.102
Preoperative serum albumin (mg/dL) 0.064
Median (range) 3.7 (2.5–4.9) 3.7 (2.5–4.9) 3.8 (2.7–4.6)
Mean ± SD 3.7 ± 0.4 3.7 ± 0.4 3.7 ± 0.4
Duration of symptoms (mo) 0.070
Median (range) 1 (0–120) 1 (0–31) 1 (0–120)
Mean ± SD 3.0 ± 9.2 2.1 ± 3.8 3.8 ± 12.4
*Data are presented as n (%) unless otherwise indicated. PJ = pancreaticojejunostomy; PG = pancreaticogastrostomy; CBD = common
bile duct; SD = standard deviation.
Bassi et al,33 Yeo et al34 and Duffas et al35 re-
ported pancreatic leakage in 13%, 12.3% and
16% of patients who had PG, and 16%, 11.1%
and 20% of patients who had PJ following PD.
One meta-analysis found that PG was associated
with a significantly lower pancreatic leakage rate
than PJ.36 Interestingly, in most retrospective
studies,37–43 the pancreatic leakage rate of PG is
approximately 0–5%, which is significantly lower
than the rate of pancreatic leakage in patients
who had PJ (13–20%). No significant difference
between the two procedures in terms of pancre-
atic leakage, however, has been reported.44–47 It
is interesting that the rate of pancreatic leakage
associated with PG varies so remarkably between
different institutions. Two possible causes of this
disparity might be differences in surgeons’ learn-
ing curves and differences in surgical technique
between surgeons. While PJ has been performed
for more than 100 years, PG has only been intro-
duced more recently. As a result, it may be too
soon to make solid conclusions regarding the
best technique.
A number of theoretical advantages have been
made regarding factors that apparently contribute
to the low leakage rate of PG. These include:
anastomosis protection against enzymatic attack
by inactivating the pancreatic proteolytic enzymes
in the relatively acid milieu of the stomach and
in the absence of enterokinase which is present
only in the small bowel; protection against mar-
ginal ulceration by neutralizing gastric acidity with
alkaline pancreatic secretions; tension-free anas-
tomosis as the pancreas lies immediately adja-
cent to the posterior wall of the stomach and the
two organs naturally opposed; absence of a long
jejunal loop which may cause tension on the anas-
tomosis by accumulation of pancreaticobiliary
Pancreaticojejunostomy and pancreaticogastrostomy
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Table 2. Observed morbidity and mortality following pancreaticoduodenectomy
Overall (n = 377) PJ (n = 188) PG (n = 189) p
Surgical mortality 19 (5.0) 15 (7.9) 4 (2.1) 0.000
Complications
Patients with complications 170 (45.1) 106 (56.4) 64 (33.9) 0.000
Pancreatic leakage 40 (10.6) 33 (17.6) 7 (3.7) 0.000
Wound infection 33 (8.8) 20 (10.6) 13 (6.9) 0.196
Delayed gastric emptying 43 (11.4) 22 (11.7) 21 (11.1) 0.857
Intra-abdominal abscess 35 (9.3) 29 (15.4) 6 (3.2) 0.000
Intra-abdominal bleeding 19 (5.0) 12 (6.4) 7 (3.7) 0.234
Upper gastrointestinal bleeding 21 (5.6) 12 (6.4) 9 (4.8) 0.493
Sepsis 15 (4.0) 13 (6.9) 2 (1.1) 0.004
Gastrojejunostomy leakage 2 (0.5) 2 (1.1) 0 0.248
Others 37 (9.8) 24 (12.8) 13 (6.9) 0.055
Postoperative hospital stay (d) 0.000
Median (range) 26 (1–134) 28 (1–134) 23 (4–106)
Mean ± SD 30.4 ± 18.8 34.8 ± 21.9 26.1 ± 13.7
Blood loss (mL) 0.064
Median (range) 800 (100–5540) 800 (100–5540) 800 (100–4500)
Mean ± SD 955 ± 684 1032 ± 798 891 ± 566
Operation time (hr) 0.000
Median (range) 7.5 (4–16) 9.0 (5–16) 6.5 (4–11)
Mean ± SD 8.0 ± 2.1 9.3 ± 2.0 6.7 ± 1.2
*Data are presented as n (%) unless otherwise indicated. PJ = pancreaticojejunostomy; PG = pancreaticogastrostomy; SD = standard
deviation.
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Type of anastomosis 0.000
PJ (n = 188) 33 (17.6) 155 (82.4)
PG (n = 189) 7 (3.7) 182 (96.3)
Pancreas texture 0.032
Soft (n = 224) 29 (12.9) 195 (87.1)
Hard (n = 136) 8 (5.9) 128 (94.1)
Pancreatic duct stenting 0.000
With (n = 185) 30 (16.2) 155 (83.8)
Without (n = 175) 8 (4.6) 167 (95.4)
Surgeon volume 0.000
Low (< 10) (n = 28) 9 (32.1) 19 (67.9)
Medium (10–20) (n = 21) 3 (14.3) 18 (85.7)
High (> 20) (n = 328) 27 (8.2) 301 (91.8)
Age 0.031
≤ 65 yr (n = 144) 9 (6.3) 135 (93.7)
> 65 yr (n = 223) 31 (13.9) 202 (86.1)
*Data are presented as n (%). PJ = pancreaticojejunostomy; PG = pancreaticogastrostomy.
Table 4. Multivariate analysis of risk factors for pancreatic leakage
Risk factor p OR 95% CI
Type of anastomosis
PJ 0.020 4.35 0.07–0.80
PG 1.00
Pancreas texture
Soft 0.085 2.11 0.90–4.94
Hard 1.00
Pancreatic duct stenting
With 0.830 1.14 0.26–2.92
Without 1.00
Surgeon volume
Low (< 10) 0.289 1.74 0.62–4.86
Medium (10–20) 0.535 1.54
High (> 20) 1.00
Age
≤ 65 yr 1.00
> 65 yr 0.031 2.54 1.09–5.92
OR = odds ratio; CI = confidence interval; PJ = pancreaticojejunostomy; PG = pancreaticogastrostomy.
Pancreaticojejunostomy and pancreaticogastrostomy
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Type of anastomosis 0.000
PJ (n = 188) 106 (56.4) 82 (43.6)
PG (n = 189) 64 (33.9) 125 (66.1)
Pancreas texture 0.001
Soft (n = 224) 115 (51.3) 109 (48.7)
Hard (n = 136) 46 (33.8) 90 (66.2)
Pancreatic duct stenting 0.002
With (n = 185) 97 (52.4) 88 (47.6)
Without (n = 175) 64 (36.6) 111 (63.4)
Surgeon volume 0.034
Low (< 10) (n = 28) 18 (64.3) 10 (35.7)
Medium (10–20) (n = 21) 9 (42.9) 12 (57.1)
High (> 20) (n = 328) 142 (43.3) 186 (56.7)
Age 0.514
≤ 65 yr (n = 144) 68 (47.2) 76 (52.8)
> 65 yr (n = 223) 102 (43.8) 131 (56.2)
*Data are presented as n (%). PJ = pancreaticojejunostomy; PG = pancreaticogastrostomy.
Table 6. Multivariate analysis of risk factors for surgical morbidity
Risk factor p OR 95% CI
Type of anastomosis
PJ 0.001 3.18 0.16–0.63
PG 1.00
Pancreas texture
Soft 0.003 2.01 1.27–3.19
Hard 1.00
Pancreatic duct stenting
With 0.291 1.44 0.73–2.86
Without 1.00
Surgeon volume
Low (< 10) 0.591 1.28 0.52–3.13
Medium (10–20) 0.521 0.73 0.28–1.92
High (> 20) 1.00
OR = odds ratio; CI = confidence interval; PJ = pancreaticojejunostomy; PG = pancreaticogastrostomy.
secretions and the weight of the loop itself; excel-
lent blood supply and the thick stomach wall is
less likely to develop ischemic complications
and holds sutures better than the jejunum loop;
early detection of bleeding from the pancreatic
remnant or the anastomosis by routine postoper-
ative gastric decompression (which also provides
constant removal of pancreatic and gastric secre-
tions ensuring that a buildup of secretions will
not cause tension on the anastomosis); direct 
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Type of anastomosis 0.009
PJ (n = 188) 15 (8.0) 173 (92.0)
PG (n = 189) 4 (2.1) 185 (97.9)
Pancreas texture 0.058
Soft (n = 224) 15 (6.7) 209 (93.3)
Hard (n = 136) 3 (2.2) 133 (97.8)
Pancreatic duct stenting 0.183
With (n = 185) 12 (6.4) 173 (93.6)
Without (n = 175) 6 (3.4) 196 (96.6)
Pancreatic leakage 0.000
Yes (n = 40) 8 (20) 32 (80)
No (n = 337) 11 (3.3) 326 (96.7)
Surgeon volume 0.000
Low (< 10) (n = 28) 6 (21.4) 22 (78.6)
Medium (10–20) (n = 21) 4 (19.0) 17 (81.0)
High (> 20) (n = 328) 9 (2.7) 319 (97.3)
Age 0.039
≤ 65 yr (n = 144) 3 (2.1) 141 (97.9)
> 65 yr (n = 223) 16 (6.9) 217 (93.1)
*Data are presented as n (%). PJ = pancreaticojejunostomy; PG = pancreaticogastrostomy.
Table 8. Multivariate analysis of risk factors for surgical mortality
Risk factor p OR 95% CI
Type of anastomosis
PJ 0.306 1.93 0.15–1.83
PG 1.00
Pancreatic leakage
Yes 0.010 4.21 1.41–12.57
No 1.00
Surgeon volume
Low (< 10) 0.004 7.27 1.87–28.29
Medium (10–20) 0.019 4.59 1.28–16.42
High (> 20) 1.00
Age
≤ 65 yr 1.00
> 65 yr 0.142 2.66 0.72–9.83
OR = odds ratio; CI = confidence interval; PJ = pancreaticojejunostomy; PG = pancreaticogastrostomy.
examination of the anastomosis by endoscopy
or roentgenography if necessary; and easy explo-
ration of the anastomosis without disassembling
the pancreatic anastomosis by opening the ante-
rior wall of the stomach if bleeding occurs.16,46,68
Some reports associated delayed gastric emp-
tying with intra-abdominal complication rather
than the type of reconstruction.49,50 In this study,
no significant difference in delayed gastric emp-
tying between PJ and PG was identified. Thus, re-
construction method did not play an important
role in delayed gastric emptying. Our data indi-
cated that soft pancreas was associated with sig-
nificantly higher pancreatic leakage by univariate
analysis, and higher surgical morbidity by both
univariate and multivariate analyses. Thus, these
results were similar with a number of studies,51–53
which reported that a soft pancreatic remnant is
more likely to develop pancreatic leakage, thereby
contributing to higher surgical morbidity.
In an attempt to prevent pancreatic leakage and
occlusion of the pancreatic duct, some studies ad-
vocate pancreatic stenting.54–57 In the present trial,
however, pancreatic duct stenting was associated
with a significantly higher pancreatic leakage
rate and surgical morbidity rate by our univariate
analysis (but not by multivariate analysis). It
should be noted, however, that pancreatic duct
stenting was performed in the majority of PJ
(90.6%), while only 15.9% of PG involved stent-
ing. It therefore appears that pancreatic duct
stenting does not play an important role in the
prevention of pancreatic leakage in the PG group.
Our data demonstrated a longer operation
time in the PJ than in the PG group. The possible
explanation is that most of the patients in the 
PJ group underwent duct-to-mucosa, which was
not performed in the PG group. Another reason
is that pylorus-preserving pancreaticoduodenec-
tomy (PPPD) was performed in 93.7% (177/189)
of our PG patients while it was only performed
in 8.5% (16/188) of our PJ patients. One meta-
analysis found that PPPD was associated with
shorter operation time and less blood loss.58 These
two reasons might be the cause of the longer op-
eration time in the PJ group than in the PG group.
In the study reported here, surgeons with
higher volume had lower pancreatic leakage rate.
This supports previous study results that reported
significantly lower rates of surgical mortality, pan-
creatic leakage and bile leakage in surgeries per-
formed by more experienced surgeons.59 Overall,
there was a higher pancreatic leakage rate in PJ
(17.6%) than in PG (3.7%) in the present study.
Pancreatic leakage-related mortality was higher
in PJ (8/33, 24.2%) than in PG (0%). The cause
of pancreatic leakage-related death in the PJ
group included intra-abdominal bleeding, intra-
abdominal abscess and sepsis. Other research
groups’ findings support these results. For exam-
ple, Takano et al reported that the mortality rate
related to pancreatic leakage was higher in PJ than
in PG (22.2% vs. 0%).43 One clear disadvantage of
PJ is that once pancreatic leakage occurs, the acti-
vated pancreatic enzymes may lead to massive
bleeding and, thus, to a life-threatening condition.
In conclusion, this study clearly demonstrated
that PG was associated with a lower surgical risk
than PJ in patients who had previously been
treated with PD in terms of pancreatic leakage,
surgical morbidity, mortality, operation time and
length of hospital stay. For the reconstruction of
pancreatic remnant after PD, we conclude that PG
is a safer procedure than PJ and should therefore
be the technique of choice amongst surgeons.
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